Please login to the form below

Not currently logged in
Email:
Password:

UK Market Access

This page shows the latest UK Market Access news and features for those working in and with pharma, biotech and healthcare.

NICE appraisal fees to be introduced despite opposition

NICE appraisal fees to be introduced despite opposition

The charges have been confirmed just days after a new 5 year UK pricing deal was finalised between the Department of Health and Social Care (DHSC) and the industry representative body

Latest news

More from news
Approximately 23 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Comment: the new UK pricing deal – welcome news, but lessons to be learned Comment: the new UK pricing deal – welcome news, but lessons to be learned

    Leslie Galloway, chairman of EMIG reflects on the new UK government-pharma industry pricing agreement. ... Leslie Galloway is chairman of the Ethical Medicines Industry Group EMIG, whose 270 member companies supply 50% of branded medicines by volume in

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Ahead of the meeting, I caught up with one of our industry speakers, Fiona Bride, head of UK market access strategy at Novartis. ... This is of particular interest because it was devised specifically for the UK market.

  • Uncertainty, austerity and Brexit Uncertainty, austerity and Brexit

    Of course, the loss is not solely confined to the UK, which provides substantial regulatory and market access expertise to the EU through the MHRA and NICE, as well as a ... Sciences Industrial Strategy and the Accelerated Access Review, leaving the UK

  • Can UK pharma rise to the post-Brexit challenge? Can UK pharma rise to the post-Brexit challenge?

    Marketing authorisations. With no access to the single market, UK pharmaceutical companies will be forced to make two separate regulatory submissions - one to the EU and one to the UK. ... This may well position the UK as a secondary or tertiary launch

  • Market access in Europe: balancing access and affordability Market access in Europe: balancing access and affordability

    European governments continue to pursue national agendas for market access, while also exploring opportunities to work together to achieve lower prices for new drugs. ... The AAR speaks of 'win-win scenarios' that effectively trade market access against

More from intelligence
Approximately 2 fully matching, plus 17 partially matching documents found.

Latest appointments

  • RJW & Partners appoints new director RJW & Partners appoints new director

    She joins the firm from pharma service provider ICON, where she served as principal and head of EU pricing and market access. ... Prior to that Beecher was with  Bristol-Myers Squibb, where she was UK pricing and market access manager, and before that

  • PM Society appoints new chairman PM Society appoints new chairman

    Bradley previously served as the PM Society's market access lead, and is brand manager for Shire's internal medicine business unit, making him the society's first chair from a ... He has since held a series of increasingly senior positions at Shire,

  • Takeda UK & Ireland appoints market access director Takeda UK & Ireland appoints market access director

    Takeda UK &Ireland has appointed Peter Wheatley Price as market access director, succeeding Ross Selby who moves to head the firm's new US-based global pricing, market access and health ... He also brings experience form Boehringer Ingelheim, where he

  • GalbraithWight appoints Eithne McShane and Steve Mazzarese GalbraithWight appoints Eithne McShane and Steve Mazzarese

    McShane (pictured right) brings experience to the role from Bayer, where she served as market access manager, Novartis Oncology and Therabel Europe. ... In her new role at UK-based market access consultancy she will be tasked with growing

  • EFPIA's Richard Torbett to move to the ABPI EFPIA's Richard Torbett to move to the ABPI

    Will take up commercial role at UK pharma bodyat the end of the month. ... At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Adelphi Research UK wins Agency of the Year at BHBIA Conference

    Adelphi Research UK’s MD Rachel Medcalf also received an award for her contribution as Chair of the BHBIA Ethics and Compliance committee. ... Adelphi Research UK is based south Manchester, in Bollington, Cheshire and is part of the Adelphi Group of

  • No Voice, No Choice

    Experts in UK market research, the agency challenges their clients to think differently by pushing the boundaries to help them drive change. ... brand communications and enabling market access.

  • 6 Ways to Make MROC’s Rock

    Adelphi Research UK are experts in GDPR with a dedicated team linked closely with BHBIA who can offer more guidance on any concerns you may have with compliance.  .

  • 6 Ways to Ensure Payer Research Delivers

    Our Market Access team has reflected on our extensive experience researching a broad range of payer audiences and come up with the following ‘musts’ for ensuring payer research sings. ... Adelphi has a dedicated Market Access consultancy to help you

  • The Biosimilar Challenge

    However, the once stable market is now under attack from a number of biosimilars that pose a significant challenge and threaten the originator brands. . ... In fact, recent self-funded work, showed that 89% of UK payers now positively endorse the use of

More from PMHub
Approximately 0 fully matching, plus 22 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics